Genomics software solution will support microbiology laboratories in identifying and reporting from raw sequencing data related to SARS-CoV-2 variants
bioMérieux, world leader in the field of in vitro diagnostic, launched EPISEQ® SARS-COV-2.
Viral mutation is a natural phenomenon leading to the emergence of variants which may have different characteristics. Currently, a number of variants of SARS-CoV-2 are circulating around the world. Some of these variants are the subject of special attention because of their impact on the pandemic (increased infectivity or severity of infection, possible vaccine escape). Genomic surveillance of the circulation of mutants is therefore essential for public health.
Launched worldwide, EPISEQ® SARS-COV-2 is a new application, intended to identify variants of SARS-CoV-2 using samples from positive patients. Automatically updated weekly, the platform identifies variants based on international nomenclatures, including any New Variants of Concern (VOCs) as defined by the World Health Organization and the Centers for Disease Control and Prevention. United States.
EPISEQ® The SARS-COV-2 is compatible with three major sequencing platforms (Illumina, Oxford Nanopore, Thermo Fisher) and easy to use by any microbiology laboratory without bioinformatics knowledge or computer resources.
The application allows the export of viral genome assemblies and mutations to facilitate reporting to national public health authorities and for epidemiological studies.
“Microbiologists today process large sets of data and must translate them into meaningful information that has an impact on clinical decisions and public health actions. EPISEQ® SARS-COV-2 fully addresses this challenge. It enables in-depth analysis of complex viral genetic sequencing data without the need for specific bioinformatics skills or major hardware investments. noted Mark Miller, executive vice president, medical director.
With its expertise in microbiology and computer science, bioMérieux has developed BIOMÉRIEUX EPISEQ®, a cloud-based genomics computing platform that helps laboratories use next-generation sequencing (NGS) technologies and interpret their results. Several NGS-based and cloud-based software modules are being developed on this platform.
“BioMérieux’s strategy is to exploit the tremendous potential of diagnostic data to support the fight against infectious diseases. Therefore, we decided earlier this year to leverage our vast and deep expertise in data science, software development and bioinformatics to develop an easy-to-use application to serve our customers using next-generation sequencing to identify SARS-CoV. -2 variants. said Pierre Boulud, COO, Clinical Operations.
Want the latest science news delivered straight to your inbox? Become a Free SelectScience Member Today >>